The Asia Pacific Intravenous Immunoglobulin Market is expected to witness market growth of 7.8% CAGR during the forecast period (2022-2028).
The term immunoglobulin refers to the breakdown of antibody-containing blood plasma. IVIg (intravenous immunoglobulin) is a blood product that is given intravenously. It's made up of polyvalent IgG antibodies collected from the plasma of thousands of blood donors. Patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia, and other kinds of hypogammaglobulinemia who are unable to make significant amounts of antibodies, get benefit from IVIg to maintain the right amount of antibodies in the body.
The comprehensive market for IVIg is divided into two categories i.e. plasma protein and therapeutic area. Polyvalent IVIg, albumin, Factor VIII, hyperimmune (IM&IV), and Factor IX are all part of the plasma protein. Immune deficiencies, autoimmune disorders, and acute infections are also included in the therapeutic area segment. The immune deficiency includes important disorders with low antibody levels, such as hypogammaglobulinemia (primary immune deficiencies), X-linked agammaglobulinemia (secondary immune deficiencies), and acquired weakened immunity syndromes (secondary immunological deficiencies). Immune thrombocytopenia and inflammatory disorders are two types of autoimmune illnesses.
The regional government and medical association are making efforts to strengthen the healthcare infrastructure in order to suit newly brought medical technology like intravenous immunoglobulin. The Ministry of Education, the Central Committee of the Communist Youth League, the State Ethnic Affairs Commission, among others, conducted different kinds of publicity and education activities for the AIDS response, depending on the respective work advantages and concentrating on such groups as teenagers, migrant workers, and women. In terms of prevention and treatment, the percentage of female sex workers living with HIV has remained relatively low in recent years.
The China market dominated the Asia Pacific Intravenous Immunoglobulin Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,150.2 million by 2028. The Japan market is poised to grow at CAGR of 7.1% during (2022-2028). Additionally, The India market is expected to display a CAGR of 8.5% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, and Others. Based on Application, the market is segmented into Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia & Myasthenia Gravis, Congenital AIDS & Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, Immune thrombocytopenia (ITP), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.
By Distribution Channel
The term immunoglobulin refers to the breakdown of antibody-containing blood plasma. IVIg (intravenous immunoglobulin) is a blood product that is given intravenously. It's made up of polyvalent IgG antibodies collected from the plasma of thousands of blood donors. Patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia, and other kinds of hypogammaglobulinemia who are unable to make significant amounts of antibodies, get benefit from IVIg to maintain the right amount of antibodies in the body.
The comprehensive market for IVIg is divided into two categories i.e. plasma protein and therapeutic area. Polyvalent IVIg, albumin, Factor VIII, hyperimmune (IM&IV), and Factor IX are all part of the plasma protein. Immune deficiencies, autoimmune disorders, and acute infections are also included in the therapeutic area segment. The immune deficiency includes important disorders with low antibody levels, such as hypogammaglobulinemia (primary immune deficiencies), X-linked agammaglobulinemia (secondary immune deficiencies), and acquired weakened immunity syndromes (secondary immunological deficiencies). Immune thrombocytopenia and inflammatory disorders are two types of autoimmune illnesses.
The regional government and medical association are making efforts to strengthen the healthcare infrastructure in order to suit newly brought medical technology like intravenous immunoglobulin. The Ministry of Education, the Central Committee of the Communist Youth League, the State Ethnic Affairs Commission, among others, conducted different kinds of publicity and education activities for the AIDS response, depending on the respective work advantages and concentrating on such groups as teenagers, migrant workers, and women. In terms of prevention and treatment, the percentage of female sex workers living with HIV has remained relatively low in recent years.
The China market dominated the Asia Pacific Intravenous Immunoglobulin Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,150.2 million by 2028. The Japan market is poised to grow at CAGR of 7.1% during (2022-2028). Additionally, The India market is expected to display a CAGR of 8.5% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, and Others. Based on Application, the market is segmented into Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia & Myasthenia Gravis, Congenital AIDS & Multifocal Motor Neuropathy, Kawasaki Disease, Guillain-Barre Syndrome, Immune thrombocytopenia (ITP), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A., Takeda Pharmaceutical Company Limited, Baxter International, Inc., Biotest AG (Tiancheng International Investment Limited), LFB S.A., CSL Limited (CSL Behring), Octapharma AG, Kedrion S.p.A, and Bayer AG.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacy
- Specialty Pharmacy
- Others
- Immunodeficiency Diseases
- Chronic Inflammatory Demyelinating Polyneuropathy
- Hypogammaglobulinemia
- Chronic Lymphocytic Leukemia & Myasthenia Gravis
- Congenital AIDS & Multifocal Motor Neuropathy
- Kawasaki Disease
- Guillain-Barre Syndrome
- Immune thrombocytopenia (ITP)
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Baxter International, Inc.
- Biotest AG (Tiancheng International Investment Limited)
- LFB S.A.
- CSL Limited (CSL Behring)
- Octapharma AG
- Kedrion S.p.A
- Bayer AG
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Intravenous Immunoglobulin Market by Distribution Channel
Chapter 4. Asia Pacific Intravenous Immunoglobulin Market by Application
Chapter 5. Asia Pacific Intravenous Immunoglobulin Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Baxter International, Inc.
- Biotest AG (Tiancheng International Investment Limited)
- LFB S.A.
- CSL Limited (CSL Behring)
- Octapharma AG
- Kedrion S.p.A
- Bayer AG
Methodology
LOADING...
